Prevents meningococcal meningitis. ANDA 80084, held by Chartwell Molecular. Sulfadiazine.
As of Nov 16, 2026, ANDA 80084 (Sulfadiazine), held by Chartwell Molecular, was first approved by FDA on Jul 5, 1978, with 7 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Sulfadiazine Tablets are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris. Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 5, 1978 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sulfadiazine500MG · tablet;oral | Sulfadiazine | Discontinued |
| Nov 14, 2024 | Supplement 20Labeling · Standard review | Approved | None posted |
| Aug 10, 2000 | Supplement 18Bioequivalence | Approved | None posted |
| Apr 22, 1991 | Supplement 10Labeling | Approved | None posted |
| Feb 8, 1991 | Supplement 9Labeling | Approved | None posted |
| Mar 6, 1990 | Supplement 7Labeling | Approved | None posted |
| Jul 26, 1983 | Supplement 5Manufacturing | Approved | None posted |
| Jul 26, 1983 | Supplement 6Manufacturing | Approved | None posted |
| Jul 5, 1978 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters